Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Baudax Bio, Inc.
  6. Summary
    BXRX   US07160F1075

BAUDAX BIO, INC.

(BXRX)
  Report
Delayed Quote. Delayed Nasdaq - 01/21 04:00:00 pm
0.195 USD   -3.61%
01/20Top Premarket Gainers
MT
01/05BAUDAX BIO : Corporate Overview
PU
01/04BAUDAX BIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
0.2018(c) 0.2038(c) 0.1964(c) 0.2023(c) 0.195(c) Last
2 064 959 3 221 725 5 843 150 75 198 490 10 549 695 Volume
+1.92% +0.99% -3.63% +3.00% -3.61% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1,31 M - -
Net income 2021 -48,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,32x
Yield 2021 -
Sales 2022 9,27 M - -
Net income 2022 -47,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,43x
Yield 2022 -
Capitalization 16,5 M 16,5 M -
Capi. / Sales 2021 12,6x
Capi. / Sales 2022 1,78x
Nbr of Employees 57
Free-Float -
More Financials
Company
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO (meloxicam) injection. ANJESO is a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. The injectable form of IV meloxicam, which utilizes NanoCrystal technology,... 
Read more
Sector
Biotechnology & Medical Research
Calendar
02/09
More about the company
Ratings of Baudax Bio, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BAUDAX BIO, INC.
01/20Top Premarket Gainers
MT
01/05BAUDAX BIO : Corporate Overview
PU
01/04BAUDAX BIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/04Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
GL
2021Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
2021BAUDAX BIO, INC. : Entry into a Material Definitive Agreement, Material Modification to Ri..
AQ
2021Health Care Stocks Edge Higher Premarket Tuesday
MT
2021Baudax Bio Plans to Raise Gross Proceeds of $4.2 Million in Preferred Stock, Warrants O..
MT
2021Baudax Bio Announces $4.2 Million Registered Direct Offering
AQ
2021BAUDAX BIO : Delisting/Failure to Satisfy Listing Rule/Transfer of Listing - Form 8-K
PU
2021BAUDAX BIO, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or S..
AQ
2021Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conferenc..
GL
2021Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conferenc..
GL
2021BAUDAX BIO : Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, ..
PU
2021BAUDAX BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
News in other languages on BAUDAX BIO, INC.
2021Les actions du secteur de la santé en hausse mardi avant le marché
2021Baudax Bio prévoit de réunir un produit brut de 4,2 millions de dollars dans le cadre d..
2021Earnings Flash (BXRX) BAUDAX BIO affiche un chiffre d'affaires de 0,3 million de dollar..
2021Earnings Flash (BXRX) BAUDAX BIO annonce un chiffre d'affaires de 201 000 $ pour le deu..
2021Baudax Bio prévoit de lever 11,9 millions de dollars dans le cadre d'un placement direc..
More news
Analyst Recommendations on BAUDAX BIO, INC.
More recommendations
Chart BAUDAX BIO, INC.
Duration : Period :
Baudax Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUDAX BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,20 $
Average target price 1,83 $
Spread / Average Target 840%
EPS Revisions
Managers and Directors
Gerri A. Henwood President, Chief Executive Officer & Director
Richard S. Casten Chief Financial Officer
Alfred F. Altomari Chairman
Stewart Mccallum Chief Medical Officer
William L. Ashton Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BAUDAX BIO, INC.-11.04%16
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508